ks6+Pf&Ô,YnRi$M^~HH  JoE-ǹy&qbw/o~?޼ C1A1uw 92b$C i456ǂ:'rjyO$JZ&aًKlnD#ƹvfvIو',v=%$TNcdgEV5iWtg\8&О1r@Җ y>e3F\  C#B(jW/#8yDG802ê[[fTF o^ӆ[XO0)D䔜J=%$+9õ@h;loj[{f:Z4*gN:®!$Cʴ>6RhM X_Oyާί9ϩ4wGD3щfљEԀTW)e4e\֠Ә}*ӓX[1%v"*DD7k.Ml MLKݷIrǮ,JpP^1bxmGˁF9%n{?Z?86;3zeS֪M<3jB Mp`L%dNw^3 ddZP^<%E`ָ N# Zf\gnM3[KJ_'Ut=QpF gh+cjT:s!7ԞԚUY u+>nU{Z `|`27 uqI"ru"Mqv=C9cX;hc-Pffq P]=8" YS\1*)k>՝_}0t$^YZ1lq#l07N"n5+a8i^& "hUM zVCA+>qOZx,VsW4E IFrD`,POSJ#Xz+6h4om̅Ři8 5(A`jh7?9hDzCCPVA81@Fqk$麮5Gff^t:^BЊº(ƃs^"X`37MZ 3<2!nc *6GLkW,sC{Y2`: R10S"ӸSmXm!u5u=7 1@1}RS :޺CL惇?܄U?hnŀ\`E,Vwǵ>h?>3º_]B|NWyiZsw@EUPQM~]8.\:K̍pXl` ~ 47,HJ- .qe3- #4[Is0FW9jY2#̺PlQG A0@;9l7 KBBN@n?+,56f?+"w^ټoPK$w!8CoL'1^f$оn67ءUasb !eܘ쥫3}sZn`ChЪ6:*YR)uߔy2:&f&9+*uJHjƓ}XNjL8_ȘRu@cޑ7/^*~q 8l,=*֞߻ß~"pw>(A?ݣaFLK*?Ow 1$mj $jl׏V~`"WqlUfa_y5O]κ.ƾqg1F3r{ iٞ0OaU fZOsKU٧ 5QK4cb ffTtirrk%6Lss}wߕ)vHlN1f3<6"bSyr͜p"e:MFLL3yC15Z9,vo[q)mԨS ,xd4YR,ݫmF>;S]&apV+2KHq&y6]y @eQ9J?:;b}3ĭY!g\OTeCO*%qA2d#dp 5w|˷ĞUbI(L]{.Rɏ7'G7O>׼FjSvON`R$H'/z[H9 ,oFcSc>f,ɬ{ah/rnh?n4O==l>i*=$c'rR~HաjU0 єz \ܩ &@@q!?O5/G3(\۝UiZ|Wm^ި5P[< +yc"=C'\:E.|`*Mz1´h&b ̛\ 7/17/07, AVP for Research and Exec. Dir. of Technology Transfer: Michael Cleare - Almanac, Vol. 54, No. 1
Print This Issue

Associate Vice Provost for Research and
Executive Director of Technology Transfer: Michael Cleare
July 17, 2007, Volume 54, No. 1


Michael Cleare

Dr. Michael J. Cleare has been named associate vice provost for research and executive director of the Center for Technology Transfer. 

Dr. Cleare will join Penn August 1 from Columbia University, where he is executive director of Science and Technology Ventures. 

Working closely with vice provost for research, Dr. Steven J. Fluharty, and other senior administrators, Dr. Cleare will help reorganize and guide Penn research-commercialization activities to improve service offerings to investigators while yielding new resources to sustain, diversify and grow the research enterprise. He will directly oversee Penn’s technology transfer office. 

In addition, Dr. Cleare will help guide Penn’s industry-sponsored research collaborations, particularly as University intellectual property plays an increasingly important role in the formation of academic-industry partnership agreements.

“President Amy Gutmann and Provost Ronald J. Daniels join me in expressing great pleasure over the opportunity to engage Mike Cleare on behalf of the University,” Dr. Fluharty said.  “Mike is very well regarded by peers, has a stellar track record as a commercialization leader in both academia and industry and will bring to the position his expert ability to form meaningful collaborations between seemingly disparate constituencies.  We consider ourselves fortunate to be in a position to call upon his expertise.”

Dr. Cleare has managed Columbia’s highly successful research-commercialization endeavors for seven years.  He was previously employed for three decades by Johnson Matthey, a world leader in advanced materials technology.  He has held a number of senior executive positions in research and development, new business development and division-level management. From 1995 to 1999, Dr. Cleare served as a parent board director for Johnson Matthey.

He received his B.S. and M.S. in chemistry from Imperial College in 1965 and his Ph.D. in chemistry from the University of London in 1970.  He pursued post-doctoral studies at Michigan State University from 1970 to 1972 with a focus on platinum anti-cancer research. Dr. Cleare was a named inventor of Carboplatin, one of the most widely used anti-cancer drugs. 

He has published more than 40 articles and papers and holds 10 patents.

Almanac - July 17, 2007, Volume 54, No. 1